ADVANCED SOLID TUMOR

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration), including non-small cell lung cancer. The trial has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. About 265 adult…

This early-phase trial is testing a new drug called DS-1103a combined with an existing cancer drug, Enhertu, in people with advanced solid tumors that have a specific genetic marker (HER2). The study aims to find a safe dose and see if the combination shrinks tumors. About 108 ad…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This study is testing an experimental drug called LBL-024 in people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 396 adults aged 18 to 80 are taking part. The drug is given…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This early-phase trial is testing a new drug called M3554, which is designed to seek out and attack cancer cells that have a protein called GD2 on their surface. The study will include up to 52 people with advanced soft tissue sarcoma or glioblastoma that has not responded to pri…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This phase 2 trial tests a new approach for people with locally advanced rectal cancer. Participants first receive a short course of radiation, followed by a combination of immunotherapy (sintilimab and IL-2) and chemotherapy (CAPOX). The goal is to see if this treatment can make…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…

This early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This early-phase study tests a new drug called GS-5319 in adults with advanced solid tumors that lack a specific gene (MTAP). The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 178 people whose cancer has not responded to s…

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…

This study tests a combination of two experimental drugs, TQB2930 and TQB2102, both designed to attack cancer cells that have a protein called HER2. The trial enrolls about 178 adults with advanced solid tumors that express HER2 and have not responded to standard treatments. The …

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

This early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…

This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 par…

This early-phase trial is testing a new drug, SKB500, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look for ear…

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This early-stage trial tests a new drug called SKB518 in 150 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug every …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-phase trial is testing an experimental drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors. Part…

This early-phase study tests the safety and best dose of SKB315, a drug designed to attack cancer cells with a specific protein called Claudin18.2. About 246 adults with advanced solid tumors that haven't responded to standard treatments will receive the drug. The goal is to see …

This study tests a new drug called SKB105 in 256 adults with advanced solid tumors that have not responded to standard treatments. SKB105 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial will first find the safest dose, then check…

This early-phase trial tests a new drug called SKB571 in 138 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. Participants recei…

This early-phase trial is testing a new daily pill called NDI-219216 for people with advanced solid tumors that have not responded to standard treatments. The study will first check safety and side effects, then look at whether the drug can shrink tumors. About 134 participants w…

This early-phase trial is testing a modified salmonella bacteria, called SGN1, in 70 people with advanced solid tumors that have not responded to standard treatments. The bacteria are designed to grow inside tumors and release an enzyme that breaks down methionine, an amino acid …

This study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an earl…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This early-stage study tests a new drug called LP-284 in about 110 adults whose lymphomas or solid tumors have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug move…

This study tests a new oral drug called AVZO-023, which blocks a protein (CDK4) that helps cancer cells grow. It is being tested alone or with other drugs in 380 adults with advanced solid tumors, especially a type of breast cancer called HR+/HER2-. The goal is to find a safe dos…

This study tests a modified salmonella bacteria (SGN1) injected directly into tumors. The bacteria are designed to grow inside tumors and cut off their food supply (an amino acid called methionine), causing the tumors to shrink. The trial involves about 70 adults with advanced so…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests an experimental drug, CLIO-8221, in 306 adults with advanced solid tumors that have spread or cannot be removed. The first phase finds the safest dose, and the second phase checks how well the drug shrinks tumors. The goal is to control the disease, not cure it, …

This study tests a new drug called SHR-4375 combined with other anti-cancer treatments in people with advanced solid tumors that no longer respond to standard care. The trial will enroll about 198 participants to check safety, find the best dose, and see if tumors shrink. It is a…

This early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack…

This study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducin…

This early-phase study tests a new drug called AM-928, given as an IV infusion, in about 38 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for ear…

This study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug i…

This early-stage study tests a new drug called HWS116 in about 56 adults with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors.…

This study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, no…

This study tests a new drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, testing how well the drug works alone or with chemotherapy in patients whose tumors have…

This study tests a new oral drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer, that have a specific RET gene change. The trial has two phases: the first finds the safest dose, and the second checks how well the dru…

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This study tests targeted cancer drugs in people with advanced solid tumors that have not responded to standard treatments. Participants receive a drug chosen based on the genetic changes in their tumor. The goal is to see if the treatment can stop or shrink the cancer for at lea…

This early-stage trial is testing a new oral drug called JBZ-001 in 25 adults with advanced solid tumors or certain blood cancers (like lymphoma) that have not responded to standard treatments. The drug works by blocking a protein cancer cells need to grow. The main goals are to …

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This study tests a new drug called VBC103 in people with advanced solid tumors that have not responded to standard treatments. VBC103 is designed to target two proteins on cancer cells to deliver a toxic payload. The trial will enroll 255 participants to find the safest dose and …

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This early-stage trial tests a new drug called BGM-2121 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug might help control th…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, …

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This early-stage trial is testing a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. Participants receive HS-20110 by IV infusion in 21-day c…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will …

This early-stage study tests a new drug called HDM2024 in 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to see if it can shrink tumors. Participants receive the drug once every three weeks,…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This early-stage trial is testing a new drug called SHR-1049 in 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look …

This study tests a new drug called CS2009, a tri-specific antibody that targets three proteins (PD-1, VEGFA, and CTLA-4) to fight advanced solid tumors. The trial has two phases: first, finding the safest dose, then expanding to see how well it shrinks tumors. About 660 adults wi…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…

This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study tests a new drug called MHB009C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and how the body ha…

This early-phase trial is testing a new drug called HCB301 in 50 adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shr…

This early-stage trial tests a genetically modified version of the Yersinia enterocolitica bacterium, given alone or with the immunotherapy pembrolizumab, in 100 adults with advanced solid tumors that have no standard treatment options. The goal is to find a safe dose and see if …

This early-stage study tests an oral gel called TRX-920 in 30 people with advanced solid tumors that no longer respond to standard treatments. The gel contains SN38, a powerful anti-cancer drug, and aims to shrink tumors with fewer side effects than the current IV version. The ma…

This study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…

This early-phase trial is testing a new drug called DB-1317 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and then expanding to see if the drug shows any signs of shrinking tumors. About 2…

This study tests a new drug called MHB048C in 200 adults with advanced solid tumors (like prostate cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug by IV, and researchers m…

This early-stage trial is testing a new drug called FS-8002, alone or combined with other treatments, in 66 people with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and get a first look at whether th…

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This study tests a new drug called MHB042C in 200 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug alone, and doctors monitor side effects and tum…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…

This early-phase trial is testing an experimental drug called DB-1310 in 1000 adults with advanced solid tumors that have worsened after standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. It is a first-in-human study, so the main…

This early-stage study tests a new drug called ABSK-011 in about 200 people with advanced solid tumors, especially liver cancer that has not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Pa…

This study tests two experimental drugs, QLP2117 and QL2107, given together to people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 149 participants will be enrolled i…

This early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This early-phase study tests a new drug called ARC101 in 70 people with advanced solid tumors that have a specific marker (Claudin 6). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have ovarian, testicular, or ot…

This early-stage study is testing a new drug called DO-2 in people with advanced solid tumors (like lung cancer) that have a specific genetic change (MET mutation) and have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it. …

This early-phase study tests an experimental drug called WJB001 in people with advanced solid tumors who have no standard treatment options left. The trial has three parts: first, finding a safe dose; second, checking how well that dose works; and third, testing it in specific tu…

This early-stage study tests a new drug called HRS-3802 in 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug …

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatmen…

This phase 2 trial is testing Envafolimab, an immunotherapy drug given as a shot, in 126 adults with advanced solid tumors that have not responded to standard treatments. The study aims to see if patients with a high number of tumor mutations respond better than those with fewer …

This study tests a new treatment called Enhanced ALPP CAR-T cells for people with advanced solid tumors that have not responded to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize and attack cancer cells that hav…

This study tests an experimental drug called VIB305 in people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. The trial has two parts: first, finding the safest dose, and then testing that dose in more patients to see if it shri…

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…

This study tests a new drug called SHR-9839 combined with other cancer treatments in people with advanced solid tumors. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. About 70 adults aged 18 to 70 with measurable tumors and good perfo…

This early-phase trial tests a new drug called VVD-159642, which targets specific cancer-driving proteins. It is given alone or with other drugs (sotorasib or trametinib) to people with advanced solid tumors that have certain genetic changes. The main goals are to check safety, f…

This study tests whether two experimental drugs, AK119 and AK112, can safely shrink or control advanced solid tumors that have stopped responding to standard treatments. About 87 adults with various solid tumors will receive the drug combination. The main goals are to check safet…

This early-stage trial is testing an engineered mitochondrial vaccine in 12 people with advanced solid tumors who cannot have standard treatments. The vaccine is given as a series of shots to see if it is safe and can help control the cancer. The study focuses on safety first, wi…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals…

This early-stage study is testing a new two-part immune therapy for people with advanced solid cancers like stomach, colon, or pancreatic cancer. The treatment combines special dendritic cells that guide the immune system to the tumor with CAR-T cells that directly attack cancer …

This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…

This phase 2 trial is testing a daily pill called JAB-21822 (Glecirasib) in 88 people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. Participants must have already tried standard treatments without success. The main goal is to see i…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This study is testing two experimental drugs, 7MW3711 and JS207, given together (with or without chemotherapy) in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking how wel…

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …

This phase 2 trial tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will check how well it works and mon…

This early-phase trial is testing a new drug called HY0001a in 261 people with advanced solid tumors who have no other treatment options. The study aims to find a safe dose and see if the drug can shrink tumors. It is currently recruiting participants.

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This study tests a new drug, MDX2004, in 235 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must be 18 or older, in good daily function, and have …

This study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…

This early-stage study tests an experimental drug called HRS-2329 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 120 participants will take…

This early-stage trial is testing a new chemotherapy drug called TR-002 in about 52 people with advanced solid tumors, including pancreatic cancer that has stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This early-stage study tests a new drug called Hemay181 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to see if the drug can shrink tumors and to check for side effects. Participants will recei…

This study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…

This pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while…

This early-phase study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and understand side effects. PLB-002 is designed to target a protein (Claudin 6) found on some…

This early-phase study tests HLX37, a new drug that targets two cancer growth pathways (PD-L1 and VEGF) at once, in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Up to 254 par…

This early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to chec…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-stage trial is testing a new drug called PQ203 in about 80 adults with advanced solid tumors, including triple-negative breast cancer, that have not responded to standard treatments. The drug is given as a weekly intravenous infusion. The main goals are to check safety…

This study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to…

This early-stage trial is testing a new drug called PLT012 in adults with advanced solid tumors that have not responded to standard treatments. PLT012 is an antibody that targets a protein called CD36 found on some cancer cells. The main goals are to find safe doses and to see if…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The drug is taken daily by mouth and works by blocking a process cancer cells need to grow. The study …

This early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find…

This early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This early-phase study is testing a new oral drug called PEP08 in up to 40 adults with advanced or metastatic solid tumors that have lost a gene called MTAP. The drug works by blocking a protein that cancer cells need to grow. The main goals are to check safety, find the right do…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This early-stage trial is testing a new drug called BAT8008 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target a protein called Trop2 found on many cancer cells. The main goals are to check safety, find the best dos…

This early-stage trial tests a new drug called PTT-4256 in 30 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumors or slows cancer …

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-stage trial is testing an experimental drug called EBC-129, both by itself and together with the immunotherapy pembrolizumab, in people with advanced solid tumours that have stopped responding to standard treatments. The study will enroll about 98 adults and focus main…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will t…

This early-phase study tests a new drug called SH009 in people with advanced solid tumors (like liver, lung, breast, or stomach cancer) that have not responded to standard treatments. The main goals are to see if the drug shrinks tumors and to check its safety. About 150 adults w…

This study tests two drugs, AL8326 and toripalimab, together in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the combination can shrink tumors. About 228 adults will take part in this early-phase tr…

This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…

This study tests an experimental drug called BMS-986482, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 413 adults will take part. Th…

This early-stage trial tests whether the experimental drug HCB101 is safe and can shrink tumors in people with advanced solid tumors or non-Hodgkin lymphoma that has come back or not responded to other treatments. About 80 adults aged 18 and older will receive the drug by IV. The…

This study tests a new drug called LM-24C5 combined with other cancer treatments for people with advanced solid tumors that have a specific protein (CEACAM5). About 130 adults aged 18-80 whose cancer has returned or not responded to standard care will participate. The goal is to …

This early-phase trial tests an experimental oral drug called HDM2006 in 48 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. Particip…

This study tests an experimental drug called HH2853 in people with certain types of blood cancer (non-Hodgkin lymphoma) or advanced solid tumors that have come back or stopped responding to treatment. The drug is taken as a tablet twice a day. The main goals are to find the safes…

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This study tests a new biologic drug called ASKG915, given alone or with standard chemotherapy, in about 594 people with advanced solid tumors that have stopped responding to other treatments. The main goals are to check safety and find the best dose. The trial is currently recru…

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This early-stage study tests a new oral drug, AXT-1003, in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug shr…

This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…

This study tests a new drug called HY07121 in 258 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV infusion. The main goals are to check safety, find the right dose, and see if it can shrink tumors. This is an early-stage t…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-stage trial is testing a new drug, BM230, in people with advanced solid tumors, especially those linked to HER2. The study has two parts: first, finding the safest dose, then expanding to see how well it works. About 123 participants will be enrolled worldwide.

This study tests a new treatment called GT307, made from a patient's own tumor-fighting immune cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the treatment is safe and to find the best dose.

This study tests a new drug called HRS-7058 combined with other cancer drugs in 300 adults with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose and see if the combination is safe and shrinks tumors. Participants must have …

This early-stage trial is testing an experimental drug called SWA1211, taken as a daily tablet, in 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shows any signs…

This study tests a new drug, FZ-AD004, for the first time in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if it can shrink tumors. About 121 adults aged 18 to 75 will take part.

This study tests a new drug called 3H-10000, which is an antibody-drug conjugate designed to target and kill cancer cells. It is for people with advanced lung or stomach cancer that cannot be removed by surgery or has spread. The trial will enroll 170 participants to find the saf…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This study tests an experimental drug called JAB-23E73, taken as a pill, in people with advanced solid tumors that have a KRAS gene change. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors. About 334 participants will be enrolled acros…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to better fight canc…

This early-stage trial tests a new drug called CUSP06 for people with ovarian cancer that has stopped responding to platinum chemotherapy, as well as other advanced solid tumors. CUSP06 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells t…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This study tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants take the pill by m…

This early-phase trial is testing a new drug called INI-4001, which is designed to activate the immune system to fight advanced solid tumors. About 50 adults with cancers that have spread or cannot be removed will receive the drug alone or combined with standard immunotherapy dru…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This early-stage trial is testing a new drug called IL12-L19L19 (Dodekin) in 80 adults with advanced or metastatic solid tumors that have stopped responding to standard immunotherapy. The drug combines an antibody with an immune-boosting protein to target and attack cancer cells.…

This early-stage trial tests a new drug called HS-20122 in people with advanced solid tumors who have no other treatment options. The study aims to find the safest dose and check for side effects. Up to 1,050 participants will receive the drug intravenously and be monitored close…

This early-phase trial tests an experimental drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in 27 people with advanced solid tumors who have no standard treatment options left. The main goal is to check safety and find the right dose, while also looking…

This study tests an experimental drug called SPH4336, given alone or with another drug (cadonilimab), in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the treatment can slow or stop cancer growth. About 63 participants will take part i…

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. A…

This Phase 1 trial is testing TJ101, an experimental antibody-drug conjugate that delivers chemotherapy directly to cancer cells. It is for adults with advanced or metastatic solid tumors (lung, prostate, esophageal, and others) who have run out of standard options. The study aim…

This study is testing an experimental drug called SHR-7787 combined with other anti-cancer medicines in 400 people with advanced solid tumors that cannot be removed by surgery. The goal is to find safe doses and see if the combination can shrink tumors or slow cancer growth. Part…

This study tests an experimental drug called SHR-1681 in 300 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and how…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in 130 people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first to find the safest dose, then to see how well the combo works against di…

This study tests a drug called CRB-701, which is designed to find and attack cancer cells that have a protein called Nectin-4 on their surface. The trial includes 348 adults with advanced solid tumors that have not responded to standard treatments. Researchers aim to find a safe …

This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…

This early-phase trial is testing a new drug, SIBP-A19, in 156 people with advanced solid tumors who have no other standard treatment options. The main goals are to check the drug's safety, find the best dose, and look for early signs that it might shrink tumors. The drug is give…

This early-stage study tests a new drug called ASD141 in 21 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the drug an…

This early-stage trial tests a new drug called SIBP-A17 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER2 found on some cancer cells. The study aims to find the safest dose and understand how the drug works…

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants will re…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This study tests a new drug called ZGGS18 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 222 participants will take part in this early-phase trial.

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the…

This early-stage trial tests a new drug called GenSci143 in 180 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can control tumor growth. Participants receive the drug by in…

This study tests a new drug called OBI-902 in people with advanced solid tumors that have not responded to standard treatments. The trial has three parts: first, finding the safest dose; second, checking how well it works in certain cancers; and third, comparing doses to pick the…

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…

This early-stage trial tests an experimental tablet called ZX-8177 in 80 Chinese patients with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and check for any signs that the drug can shrink tumors. It is a first step …

This early-stage study tests a new drug, BRY812, in 164 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug every three w…

This early-phase study is testing a new drug called AP601 in 36 people with advanced solid tumors that have not responded to standard treatments. AP601 is a bispecific antibody designed to target a protein called CD73 found on some cancer cells. The main goal is to find the safes…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This early-phase trial tests whether combining three drugs—axatilimab, retifanlimab, and paclitaxel—is safe and effective for people with advanced or metastatic solid tumors. The study will enroll 38 adults whose cancer has spread or not responded to prior treatment. Researchers …

This early-stage study tests a new drug, HW071021, in 76 adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have spread or come back. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. Participa…

This study tests a new drug called 7MW4911 in 200 people with advanced solid tumors that have worsened after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is the first time this drug is being tested in human…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study tests a new drug called YL242, given alone or with other treatments, for adults with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 participants will take part in this early-phase t…

This early-stage study tests a new drug called GenSci140 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 170 adults in China will take part,…

This early-phase study tests a new drug called ASKC202, given alone or with another drug (ASK120067), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. A…

This study tests a new drug called HYP-6589, alone or with other cancer drugs, in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and shrinks tumors. About 115 adults aged 18–80 with certain genetic marker…

This study tests a new drug called SHR-7367 combined with other cancer treatments for people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 100 adults aged 18 to 75 with measurable tumors and good organ function…

This study tests a new drug called LM-108, which clears certain immune cells from tumors, combined with standard chemotherapy and another immunotherapy. The goal is to see if this mix is safe and can slow or shrink advanced solid tumors. About 194 adults with advanced cancers wil…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This early-stage study tests a new drug called HRS-6208 in about 206 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow cancer growth. Participants…

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their g…

This early-stage trial tests a new drug called JMT106 in 200 people with advanced solid tumors, including lung and liver cancers, who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any sign of shrinkin…

This early-stage trial is testing a new drug called BTM-3566 in 30 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and understand side effects. Participants take the drug for 7 days on and 7 days off, and res…

This early-stage trial is testing an investigational drug called JZP898, both by itself and together with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find t…

This early-phase trial tests whether combining an experimental drug (AT1019), targeted radiation (SBRT), and an immunotherapy (PD-1 inhibitor) is safe for people with advanced solid tumors. About 12 participants will receive the combination and be monitored for side effects and t…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This early-stage study tests a new drug called AK138D1 in up to 200 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug may…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-phase trial tests a personalized therapy where immune cells (TILs) are taken from a patient's own tumor, multiplied in a lab, and infused back into the body to attack the cancer. The study includes both natural and gene-edited TILs and enrolls 30 adults with advanced s…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This phase 1 study tests an experimental therapy called FT825, a type of immune cell that is made in a lab and can be given to any patient without needing to use their own cells. It is being tested in people with advanced solid tumors that have HER2 or other markers. The study wi…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This early-stage trial is testing a new treatment called CEL001, made from natural killer (NK) immune cells, in 13 people with advanced solid tumors that have not responded to standard therapies. The main goal is to see if the injection is safe and tolerable, while also checking …

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 876 ad…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This study tests a new drug called HRS-6768 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: the first checks safety and the best dose, and the second looks at whether the drug can slow tumor growth. About 84 participa…

This early-stage trial is testing a new drug called VSV-02 in 6 people with advanced solid tumors (like melanoma, breast, or lung cancer) who have no good treatment options left. VSV-02 is a modified virus that is injected into a vein and directly into the tumor, aiming to kill c…

This study tests a new drug called QLC5508, given with other anti-cancer medicines, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 444 adults will t…

This study tests a combination of sirolimus (a targeted therapy) with several antibody-drug conjugates (ADCs) in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the combo can shrink tumors. About 444 participants…

This early-phase trial tests a new drug called OMTX705, which targets a protein found on cancer cells, either alone or with immunotherapy drugs (pembrolizumab or tislelizumab). The study includes 150 adults with advanced solid tumors who have no standard treatment options left. T…

This study tests a new drug called HY05350 in people with advanced solid tumors that have a protein called MSLN on their surface. The trial has two parts: first, finding a safe dose, and second, seeing if the drug shrinks tumors. About 262 participants who have exhausted standard…

This study tests an oral drug called LAM561 in children under 18 with advanced brain tumors (like high-grade glioma) or other solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose in up to 18 children, then testing that …

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This early-stage trial is testing a new drug, BR111, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug might slow or shrink tum…

This early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…

This study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…

This early-stage trial tests an oral tablet called BB102 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a specific protein (FGFR4) that may help control cancer growth. The study will check safety, side effects, and how the dr…

This early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…

This early-phase study tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals …

This early-stage study is testing a new drug called SHR-3821 in 162 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced or metastatic solid tumors, including non-small cell lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults aged 18 to 75 who hav…

This early-phase study tests a new experimental drug called AN4005 in about 31 people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants take the drug by mouth twice …

This early-stage study tests an experimental drug called nab-sirolimus in adults with advanced solid tumors who also have moderate liver impairment. The goal is to find a safe dose and see how the drug behaves in the body. About 28 participants will take part to help guide future…

This early-phase study tests whether adding metformin (a common diabetes drug) to standard chemotherapy or immunotherapy is safe for people with advanced solid tumors. About 60 participants will take metformin alone for two weeks, then continue it alongside their regular cancer t…

This study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…

This early-phase trial tests a new drug called STX-001, a self-replicating RNA that makes a protein to stimulate the immune system. It is injected directly into tumors, either alone or with the immunotherapy pembrolizumab (Keytruda). The study aims to find a safe dose and see if …

This early-phase trial is testing a new drug called ABL103 in people with advanced solid tumors that have not responded to standard treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The study will enroll 96 participants to evalu…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This study tests a new drug called LCB84, which targets a protein (TROP2) found on many cancer cells and delivers a toxic payload directly to them. It is being tested alone and together with an immunotherapy drug (anti-PD-1) in 300 people with advanced solid tumors that have not …

This early-stage trial is testing an experimental drug called BB-1709 in 300 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and look for early signs that it might shrink tumors. …

This study is testing an experimental drug called LM-2417, given alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. …

This study tests a new drug called IPG1094 in 60 people with advanced solid tumors that cannot be removed by surgery. The drug works by blocking a protein called MIF, which may help slow cancer growth. The trial has two parts: first, finding the safest dose, then seeing if the dr…

This early-phase trial is testing an experimental drug called PM54 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose by watching for side effects, and second, checking if the drug can shrink tu…

This early-phase trial tests an experimental oral drug called IPG7236 in people with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, then expanding to see if the drug can control tumor growth. About 196 participant…

This early-stage trial tests HLX42, a drug that targets a protein called EGFR found on some cancer cells. The drug delivers a powerful chemotherapy directly to the tumor. The study involves about 100 adults with advanced solid tumors, including non-small cell lung cancer, who hav…

This early study tests a new combination therapy for people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses a modified virus (hV01) designed to infect and kill cancer cells while boosting the immune system, plus an immunotherapy dr…

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…

This study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.

This early-stage trial is testing an oral drug called AL58805 in 40 people with advanced solid tumors who have run out of standard treatment options. The main goals are to find a safe dose, identify side effects, and understand how the drug moves through the body. Researchers wil…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This study tests a new drug called YL202 combined with other anti-cancer medicines (toripalimab or furmonertinib) in people with advanced solid tumors, including breast and lung cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 414 adults age…

This early-phase trial is testing a new drug called LM-168, alone or with the immunotherapy toripalimab, in 87 adults with advanced solid tumours that have not responded to standard treatments. The study first checks safety and the right dose, then looks for signs that the tumour…

This early-stage trial is testing a new drug called ESG406 in 556 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first find a safe dose, then expand to see if the drug can shrink tumors. The main focus is on safety a…

This early-phase trial tests a personalized cell therapy called TCR-T cells, engineered to recognize and attack cancer cells with a specific KRAS mutation. Up to 18 adults with advanced pancreatic cancer who have exhausted standard treatments will receive a single infusion of the…

This early-stage trial tests the safety and effectiveness of a new drug called JR8603 in people with advanced solid tumors, including stomach and colorectal cancers, who have not responded to standard treatments. Participants receive JR8603 by IV infusion three times per month. T…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This study tests a combination of two drugs—glumetinib (a targeted therapy) and a special form of docetaxel (chemotherapy)—in people with advanced stomach cancer or other solid tumors that have a specific genetic marker called MET overexpression. The trial has two stages: first t…

This early-phase trial is testing a new experimental drug called ABL103, given together with the approved immunotherapy pembrolizumab (Keytruda) and sometimes a chemotherapy called taxane. The study includes 65 adults with advanced or metastatic solid tumors that have worsened af…

This early-phase trial is testing an experimental drug called LM-24C5 in about 49 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shows any signs of shrinking tumors…

This early-stage trial is testing a new drug called XL309, alone or with another drug (olaparib), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abou…

This early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then expanding to see how well the dr…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This early-phase trial is testing a new biologic drug called AWT020 in 60 adults with advanced solid tumors or lymphoma that have worsened after standard treatments. The main goals are to check the drug's safety at different doses and to see how the body processes it. Participant…

This early-phase study tests a new drug called AK146D1 in 200 adults with advanced solid tumors that have worsened after standard treatments. The drug is designed to attach to two proteins (Trop2 and Nectin4) on cancer cells and deliver a toxic payload. The main goals are to chec…

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This phase I/II trial tests a radioactive tracer called 64Cu-GRIP B, which targets granzyme B—a substance released by immune cells. By using PET scans, researchers hope to see immune activity in tumors and predict whether immunotherapy will work. The study involves about 91 adult…

This study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…

This study tests whether wearing a compression stocking on one foot during antibody-drug conjugate (ADC) infusions can prevent peripheral neuropathy (nerve damage causing numbness or pain). Fifty-eight advanced cancer patients will wear a stocking on their left foot only, while t…

This study tests whether electronic surveys can help people with advanced cancer report their symptoms and care needs, so their doctors can connect them to palliative (supportive) care services sooner. About 90 adults with incurable solid tumors will participate. The goal is to s…

This study tests a new short-term psychotherapy called ORPHYS, designed to help people with advanced cancer who feel hopeless, lonely, or fearful about the future. 160 patients will be randomly assigned to either ORPHYS or standard psychological support. The goal is to see if ORP…

This early-stage study tests a new injection called SXRN in 54 cancer patients who have lost their appetite and weight due to their illness. The main goal is to see if the drug is safe and to find the best dose. Researchers will also check if it helps improve appetite and weight …

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study tests whether a Personalized Therapeutics Clinic (PTC) can lower the risk of harmful drug interactions in cancer patients. Participants get genetic testing to see how their medications interact with each other and with their genes. The goal is to help doctors prescribe…

This study looks at how the antifungal drug itraconazole changes the levels of the cancer drug HS-20093 in the body. It involves 18 adults with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The goal is to measure drug concentrations over …

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This study will analyze genetic material from stored tumor samples of 40 adults with advanced solid tumors or lymphoma. The goal is to see if molecular profiling can help identify more patients for early phase clinical trials. Researchers will track how many patients with a genet…